Using purified enzymes of human origin and patients' sera, we examined factors influencing the in vitro association of pyridoxal phosphate with aspartate aminotransferase (EC 2.6.1.1). found when asparate at 125 mmol/llter, 2-oxoglutarate at 6.7 mmol/liter and tris(hydroxymethyl)aminomethane at 90 mmol/liter were used, an increase over the 16% with phosphate buffer [Clin. Chem. 19, 92 (1973)]. Absorbance spectra suggest pyridoxal phosphate exists as the Schiff base of tris(hydroxymethyl)aminomethane or aspartate, or both, under conditions of assay incubation (without addition of 2-oxoglutarate). Nonenzymatic catalysis of the reaction by pyridoxal phosphate alone or a formation of a protein/pyridoxal phosphate adduct was discountedwith use of D-asparate substrates.
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Using purified enzymes of human origin and patients' sera, we examined factors influencing the in vitro association of pyridoxal phosphate with aspartate aminotransferase (EC 2.6.1.1). The rate of association was markedly retarded by phosphate buffer In comparison with tris(hydroxymethyl)aminomethane or six other buffers. Pyridoxal phosphate at an incubation concentration of 130 imol/lfter reactivated the entire apoenzyme portion of an apoenzyme/holoenzyme mixture within 5 mm in tris(hydroxymethyl)aminomethane; in contrast, less than 20% was associated during 15 mm in phosphate.
Activity measured in tris(hydroxymethyl)aminomethanebuffer without exogenous pyridoxal phosphate was 4% greater than that in phosphate and was slightly increased by Increasing the pH of the assay mixture from 7.5 to 8.0. Aspartate in the incubation medium did not retard the stimulation in tris(hydroxymethyl)aminomethane buffer.While the magnitude of stimulation varied greatlyamong sera, a consistent mean stimulation of 30% for groups of sera with normal activities was found when asparate at 125 mmol/llter, 2-oxoglutarate at 6.7 mmol/liter and tris(hydroxymethyl)aminomethane at 90 mmol/liter were used, an increase over the 16% with phosphate buffer [Clin. Chem. 19, 92 (1973) ]. Absorbance spectra suggest pyridoxal phosphate exists as the Schiff base of tris(hydroxymethyl)aminomethane or aspartate, or both, under conditions of assay incubation (without addition of 2-oxoglutarate). Nonenzymatic catalysis of the reaction by pyridoxal phosphate alone or a formation of a protein/pyridoxal phosphate adduct was discountedwith use of D-asparate substrates.
In 1955, Karmen (1) introduced the malate dehydrogenase/NADH-coupled assay for measurement of AspAT' activity in serum buffered with a phosphate buffer, pH 7.4. There have been numerous later mod- Chemists, Las Vegas, August 18-23, 1974 . 
Materials and Methods

Purified cytoplasmic
AspAT was prepared from human erythrocytes or liver by essentially the method of Rej et al. (21) and Tricine, pH 8.0. Because the substrates were added as free acids, the pH was adjusted with NaOH, and HC1 was not used (chloride affects the activity of this enzyme). All buffers were prepared to give a reagent concentration of 100 mmol/liter, equivalent to 90 mmol/liter in the final reaction mixture. The apoAspAT/holo-AspAT mixture was diluted with fraction V human albumin (50 gfliter) to 135 U/liter, determined by assay without pyridoxal-P in phosphate buffer, and was assayed in each buffer system by the following protocol:
A 2.6-ml portion of substrate (without 2-oxoglutarate) was incubated to reach 30 #{176}C; 200 il of sample was added and incubated for varying periods up to 20 mm; and 2-oxoglutarate solution in respective buffer was added and mixed. The reaction rate was continuously monitored. Pyridoxal-P was present in all but control assays at 130 imol/ liter of incubation medium. For incubations at zero time, 2-oxoglutarate was added just before the AspAT solution.
The results for two buffer systems are shown in Figure 1 . At zero time, with no preincubation of enzyme material, recombination of the apoenzyme and pyridoxal-P is about 70% complete in Tricine, whereas no stimulation is observed in phosphate. In the Tricine system recombination is complete after 5 mm. All the other organic buffers listed above gave the same result. In phosphate, however, stimulation is less than 20% complete after 15 mm. Thus only phosphate, the buffer most commonly used in such assays, effectively inhibits the recombination in the presence of aspartate.
The time course of reassociation with pyridoxal-P in Tris buffer is shown in Table 1 . Here a holoenzyme/apoenzyme mixture in 5% albumin was used as a sample, and activity was measured after various incubation times in the presence of pyridoxal-P, 130
tmol/liter. The incubation medium was Tris, pH 8.0, Control activity, in the absence of pyridoxal-P, was slightly higher in each of the organic buffers examined than in phosphate. Figure 1 shows the control activity in Tricine to be about 5% higher than in phosphate, as was also true for Tris buffer at pH 8.0.
We therefore compared the activity of human sera 2). This was further examined by using purified cytoplasmic enzyme in these two buffer systems at both pH 7.5 and 8.0. The results in both cases ( Figure 3 ) was significant at P <0.0005 by paired ttest.
The absorbance spectra of pyridoxal-P at 93 tmol/ liter in phosphate and Tris buffers are shown in Figure 4 , with the respective buffers in the reference beam.
A serum with an elevated AspAT activity (41 UI liter) was assayed at various pyridoxal-P concentrations (0-312 tmolIliter) in two substrates, one con- identical to Tris and Tricine ( Figure 1 , Table 1 ). The inhibition is apparently a function of phosphate. The buffers were tested at either pH 7.5 or 8.0, based on the pK of the particular buffer. Using a mixed buffer system of acetate/phosphate/borate, we have determined (unpublished data) that the optimal pH for cytoplasmic AspAT of human origin is 8.0, but there is a broad pH range (about 7.4-8.6) where the activity is >95% of maximum. The data presented in Table 2 (Table 2 ) and for AspAT in patient sera (Figure 2 ). We ascribe this to a slight inhibition caused by phosphate at 90 mmol/liter in the final assay mixture or else to a difference in ionic strength, which would be greater with phosphate than with Tris in equimolar concentrations at pH 7.5-8.0. (14) , in contrast, showed higher rat liver cytoplasmic AspAT activity with phosphate than with Tris HC1 buffer, as well as increasing activity with increasing phosphate concentration from 0 to 80 mmol/liter. Although differences in experimental design cannot be excluded, this may be another instance of biochemical differences between enzymes of human and nonhuman origin.
Nisselbaum
The increased activity found with the organic buffers could not be ascribed to increased activity of glutamate dehydrogenase (EC 1.4. mmollliter, indicating that in this medium also pyridoxal-P may exist as a pyridoxal-P/aspartate Schiff base. The complementary spectrum in a Tris/aspartate medium is indistinguishable from curve B, so we don't know what fraction of pyridoxal-P is in a Schiff base form with Tris or aspartate.
In any case, because reactivation of apoenzyme with pyridoxal-P in a
Tris/aspartate medium is rapid (Tables 1, 3) , there is no interference with enzyme activity if the Tris/pyridoxal-P form is initially bound to the enzyme, as might have been anticipated. Figure 4 also shows decreased absorbance of the Schiff base form at 340 nm and a more intense absorbance maximum from 380 to 420 nm. Incubation of bovine and human serum albumins (fraction V) with pyridoxal-P gave rise to slight but 31% in the routine assay (P < 0.001) and 52% in the research assay (P <0.001). When the two pyridoxal-P-supplemented assays were directly compared, the research assay gave results 18% higher than the routine assay (P <0.001).
These data indicate that a portion of the apo-AspAT is of mitochondrial origin; this is presently being investigated.
The average increase effected by pyridoxal-P in the normal range (<24 U/liter without exogenous pyridoxal-P) by the routine assay was 32% (n = 21 sera). The mean ± 1 SD values for this group were: without pyridoxal, 13.7 ± 5.2 U/liter; with pyridoxal, 18.1 ± 5.5. Applying
Tonks's formula (31) for describing allowable limits of error (%) and assuming that the normal ranges for these data3 are x ± 2 SD, the allowable limits of error are: for the nonsupple-1 These ranges are for the purposes of discussion only, as the dis. tribution is clearly non-gaussian. However, the range found with. out pyridoxal (4-24 U/liter) is very close to the normal range expecte4 for this method, i.e., somewhat higher than the 6-22 U/liter range we have found (23) with the assay in phosphate buffer at pH 7.5. Furthermore, since ratios are discussed any error in estimation of these ranges is minimized. mented system, ±37.2%; for the system with pyri- in our routine assay and about 52% in our research assay. Horder (manuscript in preparation), using a system similar to our research assay, has found an average stimulation of about 45% for sera with normal
AspAT activities. The system we propose allows reassociation within 5 mm and eliminates the need for a prior, separate incubation. Rosalki and Bayoumi (34) suggest that the degree of activation ascribable to pyridoxal-P differs in sera from patients with different disorders; this supports our speculation that the degree of stimulation may be of diagnostic value. We conclude therefore that addition of pyridoxal-
